for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Rad Laboratories, Inc.

BIO.N

Latest Trade

334.51USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

220.10

 - 

347.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
334.51
Open
--
Volume
--
3M AVG Volume
4.63
Today's High
--
Today's Low
--
52 Week High
347.37
52 Week Low
220.10
Shares Out (MIL)
29.80
Market Cap (MIL)
9,914.32
Forward P/E
46.78
Dividend (Yield %)
--

Next Event

Q3 2019 Bio Rad Laboratories Inc Earnings Release

Latest Developments

More

Bio-Rad Files New Lawsuit Against 10X Genomics For Patent Infringement

(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1)

Bio-Rad Posts Q2 EPS Of $19.86

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Industry

Scientific & Technical Instr.

Contact Info

1000 ALFRED NOBEL DR

+1.510.7247000

http://www.bio-rad.com/

Executive Leadership

Norman D. Schwartz

Chairman of the Board, President, Chief Executive Officer

Ilan Daskal

Chief Financial Officer, Executive Vice President

Andrew J. Last

Chief Operating Officer, Executive Vice President

Timothy Scott Ernst

Executive Vice President, General Counsel, Secretary

Michael Crowley

Executive Vice President - Global Commercial Operations

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

2.1K

2017

2.2K

2018

2.3K

2019(E)

2.3K
EPS (USD)

2016

0.950

2017

2.010

2018

5.840

2019(E)

7.150
Price To Earnings (TTM)
11.90
Price To Sales (TTM)
4.33
Price To Book (MRQ)
1.82
Price To Cash Flow (TTM)
10.00
Total Debt To Equity (MRQ)
8.22
LT Debt To Equity (MRQ)
8.18
Return on Investment (TTM)
13.02
Return on Equity (TTM)
12.20

Latest News

Latest News

CORRECTED-(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1)

* Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION

BRIEF-Bio-Rad Q1 Earnings Per Share $21.77

* Q1 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S

BRIEF-Bio Rad Laboratories Says CEO Norman Schwartz's 2017 Total Compensation Was $5.4 Mln Vs $4.9 Mln In 2016

* BIO RAD LABORATORIES INC SAYS CEO NORMAN SCHWARTZ'S 2017 TOTAL COMPENSATION WAS $5.4 MILLION VERSUS $4.9 MILLION IN 2016 – SEC FILING Source text: (https://bit.ly/2KCpD6p) Further company coverage:

BRIEF-Bio Rad Laboratories Says KPMG Notified Senior Management It Required More Time To Complete Audit Of 2017 Financial Statements

* BIO RAD LABORATORIES - KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS - SEC FILING

BRIEF-Bio Rad Laboratories Files For Non-Timely 10-K - SEC Filing

* BIO RAD LABORATORIES FILES FOR NON-TIMELY 10-K - SEC FILING Source text (http://bit.ly/2FeZn29) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Bio-Rad Q4 Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Bio-Rad Gains Additional U.S. FDA Clearances

* BIO-RAD GAINS ADDITIONAL U.S. FDA CLEARANCES FOR BLOOD TYPING PRODUCTS, EXPANDING ITS OFFERING FOR BLOOD TESTING MARKET Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program

* BIO-RAD AUTHORIZES NEW $250 MILLION SHARE REPURCHASE PROGRAM

BRIEF-Bio Rad Laboratories reports Q3 earnings per share $0.91

* Bio Rad Laboratories Inc reports third-quarter 2017 financial results

BRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint

* U.S. U.S. International Trade Commission says it will investigate certain microfluidic devices by 10x Genomics Inc after complaint by Bio-rad Laboratories Inc and Lawrence Livermore National Security LLC. Source text for Eikon: Further company coverage: (Reporting By Susan...

BRIEF-Bio-Rad reports Q2 earnings per share $0.17

* Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S

BRIEF-Virbac signs a research agreement with Bio-Gene

* VIRBAC SA - VIRBAC SIGNS A RESEARCH AGREEMENT WITH BIO-GENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay​

* Bio Rad Laboratories Inc - has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad introduces enhanced options with its IH-COM data management software

* Bio-Rad introduces enhanced options with its IH-COM data management software for managing patient results with the IH-1000 system Source text for Eikon: Further company coverage:

BRIEF-Amicogen buys 9.1 pct stake in Bio-Works Technologies AB

* Says it has acquired 895,000 shares in Bio-Works Technologies AB, and is holding 9.1 percent stake in the co, from 0 percent stake

BRIEF-Autobio Diagnostics to invest in 75 pct stake in bio-tech firm Bio-top

* Says it plans to invest up to 202.5 million yuan ($29.32 million) for 75 percent stake in Beijing-based bio-tech firm Bio-top

BRIEF-Bio-Rad Laboratories reports Q1 earnings per share $0.41

* Q1 revenue $500.1 million versus I/B/E/S view $477.8 million

Fitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) AUSTIN, April 05 (Fitch) Fitch Ratings has affirmed the ratings of Bio-Rad Laboratories, Inc. (Bio-Rad), including the 'BBB-' Issuer Default Rating (IDR). The ratings apply to approximately $437 million of debt...

BRIEF-Bio Rad Laboratories management intends to three people for election to its board

* Management intends to propose Jeffrey Edwards, Gregory Hinckley and Arnold Pinkston for election to its board of directors

BRIEF-Bio-Rad to acquire Raindance Technologies, Droplet Intellectual Property

* Bio-Rad to acquire Raindance Technologies and Droplet Intellectual Property

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up